Evidence map›Paper›PMID 32780924›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2021

MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project.

I Stefanaki, A J Stratigos, K P Kypreou, E Evangelou, S Gandini, P Maisonneuve, D Polsky, D Lazovich, J Newton-Bishop, P A Kanetsky and 15 more

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 7 countries.

I Stefanaki1st Department of Dermatology, Medical School, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0002-2964-370X
A J Stratigos1st Department of Dermatology, Medical School, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
K P Kypreou1st Department of Dermatology, Medical School, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
E EvangelouDepartment of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.
S GandiniMolecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
P MaisonneuveDivision of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
D PolskyThe Ronald O. Perelman Department of Dermatology, New York University School of Medicine, NYU Langone Health, New York, NY, USA.ORCID https://orcid.org/0000-0001-9554-5289
D LazovichDivision of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA.
J Newton-BishopSection of Epidemiology and Biostatistics, Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
P A KanetskyDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID https://orcid.org/0000-0002-5567-9618
S PuigMelanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Centro de Investigación Biomédica August Pi I Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universitat de Barcelona, Barcelona, Spain.
N A GruisDepartment of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-5210-9150
P GhiorzoDepartment of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
C PellegriniDermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
A De NicoloCancer Genomics Program, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
G RibasDptd. Oncologia medica y hematologia, Fundación Investigación Clínico de Valencia Instituto de Investigación Sanitaria- INCLIVA, Valencia, Spain.
G GuidaDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "A. Moro", Bari, Italy.
J C Garcia-BorronDepartment of Biochemistry, Molecular Biology and Immunology, University of Murcia and IMIB-Arrixaca, Murcia, Spain.ORCID https://orcid.org/0000-0002-9192-588X
M C FargnoliDermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.ORCID https://orcid.org/0000-0002-7249-2556
H NanDepartment of Epidemiology, Richard M. Fairbanks School of Public Health, IU Melvin & Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA.
M T LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.
J LittleSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
F SeraDepartment of Public Health, Environments and Society, London School of Hygiene & Tropical Medicine, London, UK.
S RaimondiMolecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID https://orcid.org/0000-0003-4673-9049
M-SKIP Study Group
National and Kapodistrian University of Athens · GRIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of L'Aquila · ITCentre for Biomedical Network Research on Rare Diseases · ESEuropean Institute of Oncology · ITINCLIVA Health Research Institute · ESIndiana University Health · USInstituto Murciano de Investigación Biosanitaria · ESIstituto Oncologico Veneto · ITLeiden University Medical Center · NLMoffitt Cancer Center · USNational Cancer Institute · USNYU Langone Health · USOspedale Policlinico San Martino · ITRoyal Society of Tropical Medicine and Hygiene · GBUniversity of Bari Aldo Moro · ITUniversity of Ioannina · GRUniversity of Leeds · GBUniversity of Minnesota · USUniversity of Ottawa · CA

Funding

Genetic EpidemiologyZIACP005803 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GOLDSTEIN, ALISA · 2009 to 2025
$24.8M
Genetic Epidermiology of MelanomaR01CA083115 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BISHOP, DAVID TIMOTHY, ELDER, DAVID ERIC · 2001 to 2017
$13.0M
Molecular Epidemiology of MelanomaR01CA092428 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KANETSKY, PETER A · 2002 to 2006
$2.3M
RETINOID IN CHEMOPREVENTION OF PRIMARY MELANOMAP01CA075434 · NCI · UNIVERSITY OF PENNSYLVANIA · PI REBBECK, TIMOTHY R · 1997 to 2000
$935k
MELANOMA AND ALLELIC VARIATION IN THE MCIR GENEK07CA080700 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KANETSKY, PETER A · 2000 to 2005
$634k
Cancer Research UK 10589Cancer Research UK 19167Cancer Research UK C588/A10721Cancer Research UK C588/A19167Intramural NIH HHS ZIA CP005803NCI NIH HHS K07 CA080700NCI NIH HHS R01 CA083115NCI NIH HHS R01 CA092428
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MelanomaNevus, PigmentedSkin NeoplasmsCase-Control StudiesHumansReceptor, Melanocortin, Type 1Risk FactorsMC1R protein, humanReceptor, Melanocortin, Type 1

Identifiers

PMID32780924
PMCPMC8327925
OpenAlexW3048542426

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.